Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Elaine V Jones is Director at Nextcure. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jun 22, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
NextcureNXTC
Jun 18, 20262,340disclosed Jun 22
DetailsOfficial recordElaine V Jones bought shares on the open market in 2023, and has not bought since 2023.
Elaine V Jones reported 1 open-market purchase and 0 sales since 2023; purchases in 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $7.8K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Elaine V Jones bought shares on the open market in 2023, and has not bought since 2023.
In SEC filings since 2023: the latest open-market purchase is from 2023; no open-market sale is on record.
Cytomx Therapeutics (CTMX), from 2023 to 2023: 1 purchase and 0 sales.
Elaine V Jones reported 1 open-market purchase and 0 sales here, 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.